http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Oct 2026 07:47:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/IDEXX+Laboratories+%28IDXX%29+PT+Lowered+to+%24750+at+JPMorgan/27195755.html JPMorgan analyst Chris Schott lowered the price target on IDEXX Laboratories (NASDAQ: IDXX) to $750.00 (from $775.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/IDEXX+Laboratories+%28IDXX%29+PT+Lowered+to+%24750+at+JPMorgan/27195755.html Fri, 16 Oct 2026 07:47:18 -0400 IDXX http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Starts+IDEXX+Laboratories+%28IDXX%29+at+Buy/27194878.html <p>Goldman Sachs analyst Matt Dellatorre initiates coverage on IDEXX Laboratories (NASDAQ: IDXX) with a Buy rating and a price target of $740.00.</p> <p>For an analyst ratings summary and ratings history on IDEXX Laboratories <a href="http://www.streetinsider.com/rating_history.php?q=IDXX">click here</a>. For more ratings news on IDEXX Laboratories <a href="http://www.streetinsider.com/stock_lookup_news.php?q=IDXX&amp;type=analyst">click here</a>.</p> <p>Shares of IDEXX Laboratories closed at $547.18 yesterday.</p> http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Starts+IDEXX+Laboratories+%28IDXX%29+at+Buy/27194878.html Fri, 16 Oct 2026 04:20:14 -0400 IDXX http://www.streetinsider.com/New+Coverage/KeyBanc+Starts+IDEXX+Laboratories+%28IDXX%29+at+Sector+Weight/27173122.html <p>KeyBanc analyst Steve Dechert initiates coverage on IDEXX Laboratories (NASDAQ: IDXX) with a Sector Weight rating.</p><p>The analyst comments: “We view IDXX as a high-quality company with great potential for its innovation platforms (Cancer Dx and inVue Dx), supported by our proprietary survey work (pages 29-35). However, we expect U.S. vet visits to remain soft for at least the next couple of years due to macro dynamics. We expect this to act as an overhang on valuation; therefore, we are initiating at SW, which we see as fair valuation at current levels. If we were to see any sustained inflection in http://www.streetinsider.com/New+Coverage/KeyBanc+Starts+IDEXX+Laboratories+%28IDXX%29+at+Sector+Weight/27173122.html Mon, 12 Oct 2026 02:26:35 -0400 IDXX http://www.streetinsider.com/Analyst+Comments/KeyBanc+Starts+IDEXX+Laboratories+%28IDXX%29+at+Sector+Weight/27173122.html <p>KeyBanc analyst Steve Dechert initiates coverage on IDEXX Laboratories (NASDAQ: IDXX) with a Sector Weight rating.</p><p>The analyst comments: “We view IDXX as a high-quality company with great potential for its innovation platforms (Cancer Dx and inVue Dx), supported by our proprietary survey work (pages 29-35). However, we expect U.S. vet visits to remain soft for at least the next couple of years due to macro dynamics. We expect this to act as an overhang on valuation; therefore, we are initiating at SW, which we see as fair valuation at current levels. If we were to see any sustained inflection in http://www.streetinsider.com/Analyst+Comments/KeyBanc+Starts+IDEXX+Laboratories+%28IDXX%29+at+Sector+Weight/27173122.html Mon, 12 Oct 2026 02:26:35 -0400 IDXX http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html <p>Investing.com -- Piper Sandler expects veterinary visits to decline 1% to 2% in 2026 and remain roughly flat to down 1% in 2027, with industry growth driven primarily by 3% to 5% pricing increases and limited service-intensity gains.</p><p>The firm noted that the veterinary market remains caught between resilient pricing and weak underlying volumes. Cumulative veterinary inflation since 2022 has likely impacted visits and could continue to affect visits for several more years due to lower puppy growth.</p><p>More than half of survey respondents now attribute weak industry growth primarily to demand rather than staffing issues. Veterinarians have become modestly more optimistic http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html Tue, 06 Oct 2026 06:38:26 -0400 CHWY ELAN IDXX TRUP TSCO ZTS http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html <p>Investing.com -- Piper Sandler expects veterinary visits to decline 1% to 2% in 2026 and remain roughly flat to down 1% in 2027, with industry growth driven primarily by 3% to 5% pricing increases and limited service-intensity gains.</p><p>The firm noted that the veterinary market remains caught between resilient pricing and weak underlying volumes. Cumulative veterinary inflation since 2022 has likely impacted visits and could continue to affect visits for several more years due to lower puppy growth.</p><p>More than half of survey respondents now attribute weak industry growth primarily to demand rather than staffing issues. Veterinarians have become modestly more optimistic http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html Tue, 06 Oct 2026 06:38:26 -0400 CHWY ELAN IDXX TRUP TSCO ZTS http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html <p>Investing.com -- Piper Sandler expects veterinary visits to decline 1% to 2% in 2026 and remain roughly flat to down 1% in 2027, with industry growth driven primarily by 3% to 5% pricing increases and limited service-intensity gains.</p><p>The firm noted that the veterinary market remains caught between resilient pricing and weak underlying volumes. Cumulative veterinary inflation since 2022 has likely impacted visits and could continue to affect visits for several more years due to lower puppy growth.</p><p>More than half of survey respondents now attribute weak industry growth primarily to demand rather than staffing issues. Veterinarians have become modestly more optimistic http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html Tue, 06 Oct 2026 06:38:26 -0400 CHWY ELAN IDXX TRUP TSCO ZTS http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html <p>Investing.com -- Piper Sandler expects veterinary visits to decline 1% to 2% in 2026 and remain roughly flat to down 1% in 2027, with industry growth driven primarily by 3% to 5% pricing increases and limited service-intensity gains.</p><p>The firm noted that the veterinary market remains caught between resilient pricing and weak underlying volumes. Cumulative veterinary inflation since 2022 has likely impacted visits and could continue to affect visits for several more years due to lower puppy growth.</p><p>More than half of survey respondents now attribute weak industry growth primarily to demand rather than staffing issues. Veterinarians have become modestly more optimistic http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html Tue, 06 Oct 2026 06:38:26 -0400 CHWY ELAN IDXX TRUP TSCO ZTS http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html <p>Investing.com -- Piper Sandler expects veterinary visits to decline 1% to 2% in 2026 and remain roughly flat to down 1% in 2027, with industry growth driven primarily by 3% to 5% pricing increases and limited service-intensity gains.</p><p>The firm noted that the veterinary market remains caught between resilient pricing and weak underlying volumes. Cumulative veterinary inflation since 2022 has likely impacted visits and could continue to affect visits for several more years due to lower puppy growth.</p><p>More than half of survey respondents now attribute weak industry growth primarily to demand rather than staffing issues. Veterinarians have become modestly more optimistic http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html Tue, 06 Oct 2026 06:38:26 -0400 CHWY ELAN IDXX TRUP TSCO ZTS http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html <p>Investing.com -- Piper Sandler expects veterinary visits to decline 1% to 2% in 2026 and remain roughly flat to down 1% in 2027, with industry growth driven primarily by 3% to 5% pricing increases and limited service-intensity gains.</p><p>The firm noted that the veterinary market remains caught between resilient pricing and weak underlying volumes. Cumulative veterinary inflation since 2022 has likely impacted visits and could continue to affect visits for several more years due to lower puppy growth.</p><p>More than half of survey respondents now attribute weak industry growth primarily to demand rather than staffing issues. Veterinarians have become modestly more optimistic http://www.streetinsider.com/General+News/Piper+sees+veterinary+medicine+challenges+continuing+through+2027/27151503.html Tue, 06 Oct 2026 06:38:26 -0400 CHWY ELAN IDXX TRUP TSCO ZTS http://www.streetinsider.com/Press+Releases/IDEXX+Laboratories+to+Release+2026+Third+Quarter+Financial+Results/27133892.html <p> WESTBROOK, Maine--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.idexx.com&amp;esheet=54614448&amp;newsitemid=20261001226419&amp;lan=en-US&amp;anchor=IDEXX+Laboratories%2C+Inc.&amp;index=1&amp;md5=f3a3c974fb889034b4236c304ce8b642" shape="rect">IDEXX Laboratories, Inc.</a> (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. </p><p> Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.idexx.com%2Fen%2Fabout-idexx%2Finvestors%2F&amp;esheet=54614448&amp;newsitemid=20261001226419&amp;lan=en-US&amp;anchor=www.idexx.com%2Finvestors&amp;index=2&amp;md5=2716ed10fcf82b16a7d2b98544d5e3fd" shape="rect">www.idexx.com/investors</a>. An archived edition of the webcast will be available after 1:00 http://www.streetinsider.com/Press+Releases/IDEXX+Laboratories+to+Release+2026+Third+Quarter+Financial+Results/27133892.html Thu, 01 Oct 2026 11:30:00 -0400 IDXX http://www.streetinsider.com/Business+Wire/IDEXX+Laboratories+to+Release+2026+Third+Quarter+Financial+Results/27133892.html <p> WESTBROOK, Maine--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.idexx.com&amp;esheet=54614448&amp;newsitemid=20261001226419&amp;lan=en-US&amp;anchor=IDEXX+Laboratories%2C+Inc.&amp;index=1&amp;md5=f3a3c974fb889034b4236c304ce8b642" shape="rect">IDEXX Laboratories, Inc.</a> (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. </p><p> Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.idexx.com%2Fen%2Fabout-idexx%2Finvestors%2F&amp;esheet=54614448&amp;newsitemid=20261001226419&amp;lan=en-US&amp;anchor=www.idexx.com%2Finvestors&amp;index=2&amp;md5=2716ed10fcf82b16a7d2b98544d5e3fd" shape="rect">www.idexx.com/investors</a>. An archived edition of the webcast will be available after 1:00 http://www.streetinsider.com/Business+Wire/IDEXX+Laboratories+to+Release+2026+Third+Quarter+Financial+Results/27133892.html Thu, 01 Oct 2026 11:30:00 -0400 IDXX http://www.streetinsider.com/Press+Releases/Chicago+Pacific+Founders+Pet+Fund+Announces+Exit+of+CoVetAI+Following+Acquisition+by+IDEXX+Laboratories/27126295.html <div class="xn-content"> <p><i>Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicle</i></p> <p><span class="legendSpanClass"><location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>Sept. 30, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021661888" idsrc="xmltag.org" >Chicago Pacific Founders</span> ("CPF") today announced the exit of its investment in <span>CoVetAI Inc.</span> ("CoVet") following the company's acquisition by <span value="NASDAQ-NMS:IDXX" idsrc="xmltag.org" >IDEXX Laboratories, Inc.</span> (NASDAQ: IDXX). Financial terms were not disclosed.</p> http://www.streetinsider.com/Press+Releases/Chicago+Pacific+Founders+Pet+Fund+Announces+Exit+of+CoVetAI+Following+Acquisition+by+IDEXX+Laboratories/27126295.html Wed, 30 Sep 2026 09:00:00 -0400 IDXX http://www.streetinsider.com/PRNewswire/Chicago+Pacific+Founders+Pet+Fund+Announces+Exit+of+CoVetAI+Following+Acquisition+by+IDEXX+Laboratories/27126295.html <div class="xn-content"> <p><i>Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicle</i></p> <p><span class="legendSpanClass"><location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>Sept. 30, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021661888" idsrc="xmltag.org" >Chicago Pacific Founders</span> ("CPF") today announced the exit of its investment in <span>CoVetAI Inc.</span> ("CoVet") following the company's acquisition by <span value="NASDAQ-NMS:IDXX" idsrc="xmltag.org" >IDEXX Laboratories, Inc.</span> (NASDAQ: IDXX). Financial terms were not disclosed.</p> http://www.streetinsider.com/PRNewswire/Chicago+Pacific+Founders+Pet+Fund+Announces+Exit+of+CoVetAI+Following+Acquisition+by+IDEXX+Laboratories/27126295.html Wed, 30 Sep 2026 09:00:00 -0400 IDXX http://www.streetinsider.com/Analyst+Comments/IDEXX+Laboratories+%28IDXX%29+Reiterated+at+Buy+by+Stifel+Post+Veterinarian+Survey/27078276.html <p>Stifel analyst Jonathan Block reiterated a Buy rating and $675.00 price target on IDEXX Laboratories (NASDAQ: IDXX).</p><p>The analyst commented, "IDEXX Garners the Top Spot. We asked respondents to highlight their strongest and weakest relationships among the five main Animal Health manufacturers. IDEXX’s net score was again the highest (see relative to prior July 2025/October 2023 checks on page 5). Zoetis was the second strongest, and the only other manufacturer with a net positive score, although results did deteriorate from past diligence. Merck and Elanco had the weakest results respectively, with Elanco’s prior +700 bp net score improvement (relative to the http://www.streetinsider.com/Analyst+Comments/IDEXX+Laboratories+%28IDXX%29+Reiterated+at+Buy+by+Stifel+Post+Veterinarian+Survey/27078276.html Fri, 18 Sep 2026 07:54:08 -0400 IDXX http://www.streetinsider.com/Corporate+News/IDEXX+adds+tapeworm+detection+to+UK+faecal+testing+platform/27072079.html <p>IDEXX Laboratories (NASDAQ: IDXX) has expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, covering <em>Taenia</em> and <em>Echinococcus</em> species, according to a company press release.</p><p>The addition brings the total number of intestinal parasite groups detectable through Faecal Dx to seven, which now includes hookworm, roundworm, whipworm, flea tapeworm, taeniid tapeworms, <em>Cystoisospora</em>, and <em>Giardia</em> in select panels.</p><p>Taeniid tapeworm detection will be included at no additional cost in current Faecal Dx panels and profiles for IDEXX Reference Laboratories customers in the UK. Tests returning positive for taeniid tapeworms will automatically trigger a complimentary follow-up <em>Echinococcus</em> http://www.streetinsider.com/Corporate+News/IDEXX+adds+tapeworm+detection+to+UK+faecal+testing+platform/27072079.html Thu, 17 Sep 2026 05:57:30 -0400 IDXX http://www.streetinsider.com/Press+Releases/IDEXX+Expands+Faecal+Dx+Antigen+Testing+Platform+in+the+United+Kingdom+with+Taeniid+Tapeworm+Detection/27071829.html <p class="bwalignc"> <i>Expanded testing menu now detects more intestinal parasites during routine visits</i> </p> <p> WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm, including <i>Taenia</i> and <i>Echinococcus </i>species. Proven to detect up to twice as many intestinal parasite infections earlier than faecal flotation alone,1 Faecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260917879004/en/" rel="nofollow">https://www.businesswire.com/news/home/20260917879004/en/</a></p><div http://www.streetinsider.com/Press+Releases/IDEXX+Expands+Faecal+Dx+Antigen+Testing+Platform+in+the+United+Kingdom+with+Taeniid+Tapeworm+Detection/27071829.html Thu, 17 Sep 2026 03:00:00 -0400 IDXX http://www.streetinsider.com/Business+Wire/IDEXX+Expands+Faecal+Dx+Antigen+Testing+Platform+in+the+United+Kingdom+with+Taeniid+Tapeworm+Detection/27071829.html <p class="bwalignc"> <i>Expanded testing menu now detects more intestinal parasites during routine visits</i> </p> <p> WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm, including <i>Taenia</i> and <i>Echinococcus </i>species. Proven to detect up to twice as many intestinal parasite infections earlier than faecal flotation alone,1 Faecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260917879004/en/" rel="nofollow">https://www.businesswire.com/news/home/20260917879004/en/</a></p><div http://www.streetinsider.com/Business+Wire/IDEXX+Expands+Faecal+Dx+Antigen+Testing+Platform+in+the+United+Kingdom+with+Taeniid+Tapeworm+Detection/27071829.html Thu, 17 Sep 2026 03:00:00 -0400 IDXX http://www.streetinsider.com/Mergers+and+Acquisitions/IDEXX+Laboratories+acquires+AI+veterinary+software+firm+CoVetAI/27067276.html <p>IDEXX Laboratories, Inc. (Nasdaq: IDXX) announced the acquisition of CoVetAI Inc. (CoVet), a provider of AI-based ambient listening and clinical workflow software for veterinary practices. Financial terms were not disclosed.</p> <p>CoVet serves both corporate veterinary groups and independent practices across North America, Europe, Australia, and New Zealand. Its software automates clinical documentation, transcribes consultations, and streamlines communication between veterinary teams and pet owners.</p> <p>According to the press release, CoVet will be integrated into the IDEXX software ecosystem while continuing to support third-party practice management systems and non-IDEXX integrations. IDEXX states it currently has more than 10,000 clinics globally using its cloud-based practice http://www.streetinsider.com/Mergers+and+Acquisitions/IDEXX+Laboratories+acquires+AI+veterinary+software+firm+CoVetAI/27067276.html Wed, 16 Sep 2026 07:00:28 -0400 IDXX http://www.streetinsider.com/Press+Releases/IDEXX+Laboratories+Acquires+CoVetAI+to+Advance+Veterinary+Workflow+Intelligence/27067246.html <p class="bwalignc"> Acquisition strengthens IDEXX’s connected diagnostic and software ecosystem with AI-native workflow capabilities that enhance efficiency, clinical decision-making, and diagnostic utilization </p> <p> WESTBROOK, Maine--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.idexx.com%2Fen%2F&amp;esheet=54604193&amp;newsitemid=20260916581543&amp;lan=en-US&amp;anchor=IDEXX+Laboratories%2C+Inc.&amp;index=1&amp;md5=a2bdb008f7ac9ede63b2871700f104d8" shape="rect">IDEXX Laboratories, Inc.</a> (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. Serving both multipractice corporate groups and independent veterinary practices worldwide, CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing http://www.streetinsider.com/Press+Releases/IDEXX+Laboratories+Acquires+CoVetAI+to+Advance+Veterinary+Workflow+Intelligence/27067246.html Wed, 16 Sep 2026 07:00:00 -0400 IDXX http://www.streetinsider.com/Business+Wire/IDEXX+Laboratories+Acquires+CoVetAI+to+Advance+Veterinary+Workflow+Intelligence/27067246.html <p class="bwalignc"> Acquisition strengthens IDEXX’s connected diagnostic and software ecosystem with AI-native workflow capabilities that enhance efficiency, clinical decision-making, and diagnostic utilization </p> <p> WESTBROOK, Maine--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.idexx.com%2Fen%2F&amp;esheet=54604193&amp;newsitemid=20260916581543&amp;lan=en-US&amp;anchor=IDEXX+Laboratories%2C+Inc.&amp;index=1&amp;md5=a2bdb008f7ac9ede63b2871700f104d8" shape="rect">IDEXX Laboratories, Inc.</a> (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. Serving both multipractice corporate groups and independent veterinary practices worldwide, CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing http://www.streetinsider.com/Business+Wire/IDEXX+Laboratories+Acquires+CoVetAI+to+Advance+Veterinary+Workflow+Intelligence/27067246.html Wed, 16 Sep 2026 07:00:00 -0400 IDXX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IDEXX+LABORATORIES+INC++++For%3A+Aug+20++Filed+by%3A+Emerson+Andrew/26968952.html si-local-file:///var/storage/secattach/20260824/26968952.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IDEXX+LABORATORIES+INC++++For%3A+Aug+20++Filed+by%3A+Emerson+Andrew/26968952.html Mon, 24 Aug 2026 17:00:00 -0400 IDXX O.03259153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IDEXX+LABORATORIES+INC++++For%3A+Aug+20++Filed+by%3A+Emerson+Andrew/26968952.html si-local-file:///var/storage/secattach/20260824/26968952.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IDEXX+LABORATORIES+INC++++For%3A+Aug+20++Filed+by%3A+Emerson+Andrew/26968952.html Mon, 24 Aug 2026 17:00:00 -0400 IDXX O.03259153 http://www.streetinsider.com/Analyst+Comments/IDEXX+Laboratories+%28IDXX%29+Reiterated+at+Buy+by+Stifel+as+Fundamentals+Remain+Intact+/26953322.html <p>Stifel analyst Jonathan Block reiterated a Buy rating and $675.00 price target on IDEXX Laboratories (NASDAQ: IDXX).</p><p>The analyst commented, "We believe the long-term company fundamentals remain intact. IDEXX is capturing market share across multiple modalities, international momentum is increasing, and diagnostics in the veterinary office will likely continue to play an increasingly important role. Additionally, we believe that IDEXX's innovation portfolio will aid CAG Dx recurring revenue growth in coming years."</p><p>For an analyst ratings summary and ratings history on IDEXX Laboratories <a href="http://www.streetinsider.com/rating_history.php?q=IDXX">click here</a>. For more ratings news on IDEXX Laboratories <a href="http://www.streetinsider.com/stock_lookup_news.php?q=IDXX&amp;type=analyst">click here</a>.</p><p>Shares of IDEXX Laboratories closed at $562.20 http://www.streetinsider.com/Analyst+Comments/IDEXX+Laboratories+%28IDXX%29+Reiterated+at+Buy+by+Stifel+as+Fundamentals+Remain+Intact+/26953322.html Thu, 20 Aug 2026 08:13:14 -0400 IDXX http://www.streetinsider.com/Corporate+News/IDEXX+launches+point-of-care+cardiac+test+for+cats+and+dogs/26901178.html <p>IDEXX Laboratories, Inc. (Nasdaq: IDXX) announced the launch of the Catalyst proBNP Test, which the company claims is the first dual-species, in-clinic test for NT-proBNP, a biomarker used to evaluate heart disease in cats and dogs.</p><p>The test will be available on the Catalyst platform, which has a global installed base of nearly 80,000 analyzers, beginning in North America in October 2026, with international availability to follow.</p><p>NT-proBNP is used to screen, diagnose, and monitor cardiac disease in companion animals. According to published veterinary guidelines cited in the press release, heart disease affects approximately one in six cats and one in 10 http://www.streetinsider.com/Corporate+News/IDEXX+launches+point-of-care+cardiac+test+for+cats+and+dogs/26901178.html Tue, 11 Aug 2026 07:01:17 -0400 IDXX